Introduction – The Rising Healthcare Imperative in the Pacific
Demand stays steady every year. It does not change with trends or choices.
It depends on the basic health needs of people. Indian API exporters will experience the exact type of demand they see in the South Pacific.
The three countries of Samoa, Fiji and Papua New Guinea import more than 90 per cent of essential medicines.
It is not a supply chain shortage or a policy failure that can be remedied overnight.
This market works differently. It is shaped by small populations and the lack of local drug production.
For Indian API suppliers, this creates a rare opportunity. Demand is steady, repeatable, and essential. It is not optional.
Buyers in the Pacific, especially at the Fiji Ministry of Health, are now looking for more than just low prices. They are not interested in one-time deals.
They expect you to be reliable. You should understand shipping challenges in island regions. You must provide proper stability data for tropical climates. And you should stay available even months after the first deal.
Market Insight: Healthcare spending in Pacific Island countries is growing at 6-8% every year (World Health Organisation Western Pacific, 2023).
This steady growth makes long-term supply agreements a smart and stable choice for Indian exporters.
This guide is for Indian API manufacturers. It will help you whether you are entering the Pacific market for the first time or growing your current business there.
South Pacific Pharmaceutical Market Analysis (2026)
Key Regional Hubs – Fiji vs PNG at a Glance
Pacific markets are not all alike. Fiji and Papua New Guinea offer two different entry paths. You need to understand these differences before you spend on registration and distribution.
| Category | Fiji | PNG | India’s Fit |
| Population | ~930,000 | ~10 million | High-volume API packages for PNG; speciality batches for Fiji |
| Healthcare Spend CAGR | ~6% | ~8% | Sustained recurring demand for essential APIs |
| Primary Disease Burden | NCDs (diabetes, CVD) | NCDs + malaria + TB | Metformin, anti-malarials, anti-TB – all in India’s core export portfolio |
| Regulatory Body | MEHA (6-12 months) | Pharmacy Board (8-14 months) | WHO-GMP + DMF filing covers both |
| Key Port | Suva | Lae / Port Moresby | Singapore hub routes serve both efficiently |
Fiji is the entry point to the South Pacific pharma market.
It has regional distributors, active Ministry of Health buyers, and a clear system through the Fiji Medicines and Healthcare Products Authority in Suva.
When you register your API in Fiji, it becomes easier to connect with smaller Pacific countries.
Many of them look at Fiji approvals before choosing suppliers.
Papua New Guinea is different. It is a high-volume market. It has a population of over 10 million.
There is a high level of diseases like malaria and TB, along with diabetes and hypertension.
Because of this, demand is large. Donor-funded programs also place big orders, which create strong volume opportunities.
India’s Trade Position – The Numbers Make the Case
India already exports medicines to Fiji and other Pacific countries. The total value is over USD 60 million.
The Generic API industry in India is also growing fast, at about 12-15% every year.
India is now one of the top three medicine suppliers to Fiji, PNG, and Vanuatu.
This did not happen overnight. It is the result of years of competitive pricing, strong quality standards like WHO-GMP, and reliable supply.
This partnership is now stronger under the Forum of India-Pacific Islands Cooperation (FIPIC).
Under FIPIC III, India has signed agreements with 14 Pacific Island countries.
The goal was to reach USD 3 billion in trade by 2025.
Pharmaceuticals and APIs play a key role in this growth.
This means one thing: the timing is right. Indian exporters who build strong relationships and get the right certifications can benefit the most right now.
Why Indian APIs Are the Preferred Choice for Pacific Buyers
India’s Global API Standing
Buyers in the Pacific do not start from zero when choosing suppliers. They already trust India.
India supplies almost 20% of the world’s APIs. It has more than 1,500 WHO-GMP-approved plants.
This is one of the highest numbers in the world. Indian pharma businesses also supply medicines to over 200 countries.
This makes India a strong and trusted option.
In FY2024, India’s pharma exports crossed USD 27.8 billion (India Brand Equity Foundation).
This shows the trust built over time by health ministries, regulators, and pharma buyers across the world.
For a procurement officer in a Pacific health ministry, choosing an Indian supplier feels safer. The credibility is already there.
The Competitive Landscape – Why India Wins
The honest comparison looks like this:
| Factor | India | China | Australia |
| WHO-GMP Certified Plants | 500+ (global leader) | Limited WHO-GMP | Fewer, higher cost |
| Zone IVb Stability Data | Widely available | Inconsistent | Available but expensive |
| Regulatory Track Record | Proven in 200+ countries | Mixed | Strong in Oceania |
| Small Batch Flexibility | High | Low-Medium | Medium |
China is a price competitor, which often is not able to deliver Zone IVb stability data – something that is a must in Pacific registrations.
Australia is a trusted country; however, it is priced out of most generic API tenders.
India is at the crossroads of regulatory credibility, competitive prices, and tropical-grade documentation specifically demanded by the Pacific market.
APIs in Highest Demand – A Therapeutic Breakdown
The disease burden in the Pacific has a strong impact on API demand.
Indian exporters who match their products to these needs are in a better position to win first-time tenders and build long-term supply partnerships:
Metformin HCl, Amlodipine Besylate, Atorvastatin Calcium, and Losartan Potassium. These are widely used in Fiji, Samoa, and Tonga, where diabetes and heart diseases are very common. These medicines are used daily, so demand stays steady.
Amoxicillin Trihydrate, Azithromycin, Ciprofloxacin HCl. These are important in PNG and Vanuatu, where infectious diseases are still common. This keeps demand for antibiotics high.
Artemether and Lumefantrine. These are key medicines in PNG and the Solomon Islands, where malaria is still a major health issue. Large quantities are often bought through donor programs.
Rifampicin, Isoniazid. These are mainly supplied through programs supported by the World Health Organisation. Orders are often pooled, which means large and regular demand.
Quick Answer Box
Q: What is the transit time from Mumbai to Suva, Fiji?
Via Singapore, the average transit time is 18-26 days: around 8-12 days between India and Singapore, and 10-14 days between Singapore and Suva. Direct shipping is expensive and not so widespread. Most Indian exporters use the Singapore hub model. This helps them combine shipments with other cargo and reduce freight cost per kg.
Q: Which APIs are most in demand in Papua New Guinea?
Demand in PNG depends on its disease burden. Some APIs are used more often than others:
Metformin HCl and Amlodipine for diabetes and heart conditions.
Artemether and Lumefantrine for malaria
Rifampicin and Isoniazid for TB.
Amoxicillin and Ciprofloxacin for common infections.
Donor-funded programs also play a big role. Organisations like the Global Fund and Asian Development Bank support large purchases. They increase demand for anti-malarial and anti-TB APIs.
Building Trust – What Pacific Buyers Actually Require
Regulatory Documentation – The Non-Negotiables
Every Pacific procurement officer has been burned at least once by a supplier who cleared the price bid but could not produce the right documentation.
Technical credibility, in this market, is what closes deals and keeps them.
WHO-GMP Certification:
The baseline requirement for any Ministry of Health tender in the Pacific.
Without it, your inquiry does not move past the first evaluation stage.
Drug Master File (DMF):
Essential for formulator partnerships in Fiji and PNG.
A properly filed DMF signals that your API process is documented, auditable, and consistently reproducible.
Zone IVb Stability Data (40°C / 75% RH):
This is where Indian suppliers can genuinely differentiate.
Zone IVb is the most stringent ICH climate category, designed for hot, humid tropical regions.
Pacific MoH evaluators specifically look for this when assessing shelf life claims.
Suppliers who provide full Zone IVb data shorten the evaluation process significantly.
CEP (Certificate of Suitability from EDQM):
This adds strong credibility. Donor-funded buyers prefer it.
Groups like UNICEF, The Global Fund, and the Asian Development Bank trust suppliers who have CEP.
WHO Prequalification:
Mandatory for Global Fund and UNICEF tenders.
If your API strategy includes donor-funded programs in PNG or Vanuatu, this is not optional.
Certificate of Analysis (CoA) with Full Impurity Profiles:
Buyers in the Pacific now check quality more closely. A simple CoA is not enough.
You must include full impurity details based on ICH guidelines. This helps prove your product quality and builds trust.
Tropical-Grade Packaging – Not Optional, Not an Afterthought
A high-quality API is useless if it arrives damaged. In the Pacific, shipping is long and tough.
Sea journeys can take 30-60 days. There is high humidity and changing temperatures.
So, packaging must be designed for the journey, not just the final use.
Moisture-barrier pouches (foil or HDPE) are a must for island shipping routes.
Use double-seal containers for humidity-sensitive APIs like Metformin HCl.
Even one seal failure during a 45-day sea trip can damage the whole batch.
Add desiccant packs with oxygen absorbers, especially for APIs that react with air.
Include temperature data loggers in every shipment. Buyers in the Pacific now ask for full temperature records. Suppliers who provide this in advance build trust faster.
Supply Reliability – The Real Differentiator
Price helps you enter the deal. Reliability helps you stay.
Many Pacific buyers say the same thing. Some suppliers win tenders but fail later. They delay shipments, respond slowly, or deliver uneven quality.
If you want long-term business, focus on how you work, not just what you sell:
Keep clear batch traceability records. Show the full journey, from raw materials to final export.
Reply to technical questions within 24-48 hours. Fast replies build trust.
Help buyers plan ahead. Support 6-12 month demand forecasts. This reduces delays and builds stronger relationships.
Maintain a 3-6 month buffer stock for key APIs. Shipping delays are common in island regions. Buyers prefer suppliers who are prepared.
Local Language Support
Language should never be a barrier to doing business. All technical documents are provided in English.
For buyers in Fiji who speak iTaukei and buyers in PNG who communicate in Tok Pisin, queries are handled through regional distribution partners.
This means Pacific procurement teams can ask questions and get answers in a language they are comfortable with.
It is a small thing. But in a relationship-driven market like the Pacific, it builds real trust.
Decoding the Pacific Procurement Landscape
Government Tenders – The Primary Channel
Most pharmaceutical purchases in the South Pacific are handled by government health departments.
This means that understanding the tender system is not optional. It is necessary if you want to enter and grow in this market.
The Ministry of Health tender process usually starts with an open international tender.
After that, there is a technical review stage. In this stage, documents like the WHO-GMP certification, stability data, and Certificate of Analysis (CoA) are checked.
Only suppliers who meet these requirements can move forward.
Pre-qualification happens before pricing.
Suppliers must meet key standards like WHO-GMP certification, Zone IVb stability data, and full CoA documents before their prices are even considered.
Tenders are usually released once or twice a year, depending on the country.
They are listed on official Ministry of Health websites and regional tender portals. So, exporters need to track these regularly.
Pooled Procurement – The Smart Entry Strategy for Smaller Islands
Here is something many export guides miss. For smaller Pacific nations like Kiribati, Tuvalu, Tonga, and Nauru, the demand in each country is very low.
This makes it hard to justify the cost of logistics and product registration for each market separately.
A better approach is pooled procurement. One of the most important groups for this is the Melanesian Spearhead Group (MSG).
The MSG includes PNG, Solomon Islands, Vanuatu, and Fiji.
Together, they manage procurement for a combined population of over 10 million people.
When these countries combine orders for products like insulin and metformin, the total volume becomes large enough for Indian API exporters.
It also helps reduce costs by 20-40% compared to buying separately (as per World Health Organisation data).
This makes medicines more affordable for smaller health budgets.
Key Operational Note: When you apply for MSG tenders, you must send your documents to the central pooled tender coordinator, not to individual Ministry of Health offices.
If you apply to separate ministries for a pooled tender, your application may be rejected early.
The Pacific Islands Development Forum (PIDF) also supports pooled medicine procurement across Polynesian and Micronesian countries.
If you work with both MSG and PIDF systems, you can reach most of the Pacific’s main buying channels.
Donor-Funded Programs – High Volume, Clear Requirements
Papua New Guinea receives over USD 150 million in health aid each year through programs supported by the Asian Development Bank and World Bank.
In Vanuatu, grants from the Global Fund for TB and malaria also support the healthcare system.
These donor channels create large API demand, but they have strict and non-negotiable entry rules.
WHO Prequalification of Medicines is required for procurement by groups like the Global Fund and UNICEF.
Tenders from the World Bank and Asian Development Bank also treat WHO PQ as a strong sign of quality.
The entry process is clear. You need to submit an Expression of Interest (EOI) to each agency’s approved supplier list.
You must maintain WHO PQ status. You also need to register your anti-malarial and anti-TB APIs under the country programs where you plan to supply.
For Indian exporters with the right products, donor-funded channels in PNG and Vanuatu can be very valuable.
In many cases, they can justify the full investment needed to enter the Pacific market.
Strategic Roadmap for Indian API Exporters
Step 1 – Start Small, Build Smart
The biggest mistake Indian exporters make in the Pacific market is using standard MOQ thinking in a very different market.
A Pacific island with a population of 100,000 people does not need a 500 kg API shipment.
They usually need only 10-25 kg for initial testing, registration, and evaluation by their Ministry of Health.
Offering small batches of 5-50 kg for first-time orders is not a loss. It is a smart entry strategy.
You can position this as a “Pacific Islands First” program.
This means lower MOQ for new buyers, with a clear plan to increase volumes later through pooled procurement once trust is built.
This approach helps you build product data and form strong buyer relationships simultaneously.
Step 2 – Register in Fiji First
Fiji has one of the most structured regulatory systems in the Pacific.
The Fiji Medicines and Healthcare Products Authority (MEHA) is well organised and widely respected.
Registration in Fiji may take 6-12 months, but it creates a strong reference point.
Other countries like Samoa, Tonga, and the Cook Islands often look at Fiji approvals when reviewing suppliers.
So, one approval can help you enter multiple markets.
The practical registration pathway for Fiji:
Step 3 – Build Local Distribution Relationships
Entering the Pacific without local support is slow and hard. Two key hubs are Suva in Fiji and Port Moresby in PNG. These cities have strong pharma distribution networks.
A local partner does more than delivery. They help with regulatory work and stay in touch with Ministry of Health buyers, and share updates on pooled procurement cycles.
Indian-origin distributors in Fiji are a good starting point. They understand Indian suppliers and the Pacific market needs. This helps you enter faster and with less risk.
You can also connect through the Pharmaceuticals Export Promotion Council of India and the Federation of Indian Chambers of Commerce and Industry, India-Pacific forums to find trusted partners.
Step 4 – Optimise the Logistics Architecture
Shipping between India and remote Pacific islands is costly and not frequent. The Singapore hub model connects to Pacific ports and is the most common method for a clear reason.
It offers fixed schedules and lets you combine cargo with other Indian exporters. This helps reduce per kg costs and provides a safe transit point for temperature-controlled APIs.
For Melanesian routes, Sydney and Brisbane can also be used as alternative hubs. Key Pacific ports to build freight links include Suva (Fiji), Lae and Port Moresby (PNG), Port Vila (Vanuatu), and Apia (Samoa).
A practical transit guide for planning purposes:
Navigating Real Challenges in the Pacific Market
Geographic Barriers and Freight Economics
The geography of the Pacific is not a small issue. It is the main challenge when doing business in this region.
For remote island groups like Kiribati, Tuvalu, and Tonga, freight costs can be 3-5 times higher than normal Asian export routes.
This is how the market works, not a problem that can be easily fixed.
The practical solutions are simple. You can price your products on an FOB basis and let the buyer handle freight.
Or you can use the Singapore hub model to combine shipments and share freight costs across multiple buyers.
Working with logistics providers based in the Pacific is also helpful.
These partners specialise in consolidating pharmaceutical shipments.
They often have strong port connections and freight networks. These cannot be built by individual exporters on their own.
Regulatory Fragmentation – The One Pacific, Many Systems Problem
There is no single regulator like the U.S. Food and Drug Administration in the Pacific.
Each country has its own system, with different rules, timelines, and capabilities.
This makes market entry more complex than many exporters expect.
The current situation looks like this:
Fiji (MEHA, 6-12 months), PNG (Pharmacy Board, 8-14 months), Vanuatu (VANUAMED, 4-8 months), Solomon Islands (MoH, 6-10 months).
A regional regulatory alignment effort has been discussed, but progress is slow and does not help much in the short term.
The best approach is to use Fiji as your main registration base.
You invest fully in this one market and then use the approval as a reference for nearby countries.
This does not remove the need for separate registrations.
But it helps speed up approvals and builds trust with regulators who often coordinate with Fiji.
Cold Chain and API Integrity Over Long Voyages
A sea shipment from Singapore to a remote Pacific island can take up to 45 days.
During this time, temperatures can go above 30°C.
This creates a real challenge for API stability and packaging quality.
Zone IVb stability data is not just a requirement on paper.
It proves that your API can handle these conditions and still maintain its quality when it arrives.
For cold chain APIs, the process is even more strict.
You need refrigerated containers booked through logistics partners who understand Pacific routes.
You should use temperature data loggers to track conditions during the full journey.
You also need proper documentation that shows cold chain handling at both the origin and destination ports.
Pacific Ministry of Health buyers are now asking for full temperature records.
Suppliers who already have this system in place stand out clearly from those who do not.
Payment And Currency Constraints
Limited availability of foreign exchange and currency control can limit financial systems in the Pacific.
This has a direct effect on payment schedules and the structuring of deals.
Risk-mitigated approaches:
Preferred banking partners in the region:
Operating in these structures is not a choice but a necessity to predictability of cash flow and security of transactions in the smaller island economies.
Future Opportunities – The NCD Crisis & Beyond
The NCD Surge
The Pacific is facing a health emergency. It is not an infectious disease.
It is not malaria. It is non-communicable diseases, such as diabetes, heart disease, and obesity.
These conditions are now responsible for more than 75% of all deaths across Pacific Island nations.
That number comes straight from WHO data. It is one of the highest NCD death rates in the world.
The numbers behind this crisis are striking. In Fiji, more than 15% of the population lives with diabetes.
That puts Fiji among the highest diabetes prevalence rates globally.
In Samoa, over half of all adults are obese. In Tonga, the figure is even more alarming – 90% of the population is overweight or obese.
These are not projections. These are current realities.
For Indian API manufacturers, this is not just a health statistic. It is a demand signal.
The APIs needed to treat these conditions are exactly what India manufactures at scale.
Metformin, Atorvastatin, Amlodipine, Losartan, and Aspirin are the five most consistently tendered NCD APIs across the Pacific right now.
Demand for all five is growing year on year.
Looking ahead to 2026-2030, three additional categories are gaining traction fast.
Anti-obesity medications like Orlistat and Liraglutide are moving from donor-funded pilots into mainstream MoH procurement.
Insulin analogues are seeing growing demand as diabetes management improves across Fiji and PNG.
Cardiovascular combination therapies, fixed-dose combinations of antihypertensives and statins, are being introduced into Pacific essential medicines lists.
Indian manufacturers who can supply these APIs with Zone IVb stability data will be well ahead of the competition.
Local Formulation Unit Partnerships
There is a smarter way to enter this market than direct MoH tender bidding.
Supply your APIs to local formulators. Two exist in the Pacific right now.
In Fiji, the Fiji Pharmaceutical and Biomedical Services, known as FPBS, is a government-run formulator.
It produces essential medicines locally for Fiji’s public health system. It needs a reliable API supply partner.
If you can provide consistent quality, Zone IVb stability data, and competitive pricing, FPBS is a serious long-term customer.
The right move is to contact their procurement team directly.
Share your API portfolio and your stability data. Keep the conversation practical and specific.
In PNG, local manufacturing is still at an early stage. Port Moresby has emerging units producing simple tablets and capsules.
These units need an API supply but lack the procurement infrastructure of a government body like FPBS.
Relationships here are built through local distributors and trade visits rather than formal tender processes.
The advantage of supplying local formulators over the MoH tenders is significant.
You skip the complexity of finished product import registration.
You build a direct, recurring supply relationship.
And you become embedded in the Pacific’s manufacturing ecosystem, which is only going to grow as ADB and World Bank health investments increase.
Pacific Health Infrastructure Investments
Money is coming into the Pacific health sector. A lot of it.
The Asian Development Bank has committed over USD 500 million to Pacific health projects running from 2024 to 2028.
The World Bank is running health system strengthening grants across PNG, Solomon Islands, and Vanuatu.
These programmes are not just building hospitals. They include medicine procurement budgets.
They include approved supplier lists.
Getting onto those lists is the opportunity. It requires WHO-GMP certification, WHO Prequalification where applicable, and a track record of supplying to institutional buyers.
Indian API manufacturers who are already registered in Fiji, already on the WHO PQ lists, and already supplying donor-funded programmes in PNG are the ones who will capture this investment wave. It will not wait for latecomers.
Market Entry Scenarios
Scenario A – Entering Fiji as a Regional Gateway
This is the lowest-risk entry point. Fiji has the most organised regulatory system in the Pacific.
MEHA registration, while it takes 6 to 12 months, is a well-defined process.
Suva has an active distributor network. Fiji’s approval gives you credibility across neighbouring island nations.
Start with your top two or three NCD APIs. Register them with MEHA. Partner with a Suva-based distributor who monitors MoH tenders.
Bid on the annual tender cycle. Use your Fiji approval as a reference document when approaching Samoa, Tonga, and the Cook Islands.
Year one is about registration and relationship building. Year two is about winning tenders. Year three is about scale.
Scenario B – Targeting PNG via Pooled and Donor Channels
PNG is a volume market. It has a population of over 10 million and one of the highest disease burdens in the Pacific.
But it is not a straightforward market to enter without prior relationships or registrations in place.
The Pharmacy Board registration takes 8 to 14 months. The MoH tender process is competitive.
The smarter entry is through donor channels.
PNG receives over USD 150 million in annual health aid. Global Fund, UNICEF, and ADB all run active procurement programmes for anti-malarial, anti-TB, and NCD APIs.
Getting onto the WHO Prequalification lists and submitting Expressions of Interest to these agencies is the fastest route to meaningful PNG volumes.
Work with a Port Moresby-based distributor to manage in-country logistics and regulatory follow-up.
Scenario C – Small Island Strategy (Samoa, Tonga, Vanuatu)
Individual entry into Samoa, Tonga, or Vanuatu rarely makes commercial sense on its own.
The populations are small. The procurement volumes are low. The freight costs are high.
The right approach is pooled procurement. These nations group their orders through the PIDF framework.
Winning a pooled tender covers multiple islands in a single contract. Start by registering in Fiji.
Use that approval as the anchor. Then submit to the pooled tender coordinators rather than individual MoH offices.
Keep your entry MOQ flexible, 5 to 25 kg for initial registration batches.
Price competitively, but do not race to the bottom. These buyers value reliability over the lowest quote.
FAQ Section
Q1: How do I register my API in Fiji?
Registration goes through MEHA, the Medicines and Therapeutics Committee. You need a current WHO-GMP certificate for your manufacturing site, a Drug Master File, Zone IVb stability data at 40°C and 75% RH, and a full Certificate of Analysis with impurity profiles.
Q2: What is Zone IVb stability data, and why do Pacific buyers need it?
Zone IVb is the most stringent ICH climate stability category. It covers hot and humid conditions, 40°C temperature and 75% relative humidity. The Pacific sits in this climate zone. MoH buyers need proof that your API remains stable under these conditions for the full shelf life claimed on your product.
Q3: Which APIs are most in demand in Papua New Guinea?
PNG has a dual disease burden. For NCDs, the highest demand is for Metformin, Amlodipine, and Atorvastatin. For infectious diseases, Artemether and Lumefantrine dominate anti-malarial procurement. Rifampicin and Isoniazid are consistently tendered through WHO-supported TB programmes.
Q4: Does PNG accept WHO-GMP certification from India?
Yes. WHO-GMP certification by Indian manufacturers is one of the main quality credentials recognised by the PNG Pharmacy Board. Local registration will still be required, including the filing of stability data, a Drug Master File and a Certificate of Analysis.
Q5: What is the Melanesian Spearhead Group (MSG)?
The MSG is a regional bloc made up of PNG, Solomon Islands, Vanuatu, and Fiji. It coordinates trade and development across member nations, including pharmaceutical procurement. Under the MSG procurement framework, member nations pool medicine orders to increase buying volume and reduce per-unit costs.
Q6: How long does shipping take from India to Fiji?
The standard route goes through Singapore. India to Singapore takes 8 to 12 days. Singapore to Suva takes another 10 to 14 days. Total transit is roughly 18 to 26 days. Direct shipping from India to Fiji is available but expensive and infrequent.
Q7: What MOQ do Pacific buyers expect?
Standard export MOQs do not work in the Pacific. Island nations have small populations and limited storage capacity, so large shipment quantities are rarely practical. Buyers normally require 5 to 50 kg of initial registration batches. After creating a relationship and activating pooled procurement, volumes become very big. Create your proposal with a low entry MOQ and an established scale-up route.
Q8: Is English sufficient for documentation in Pacific markets?
Yes. English is the official language of pharmaceutical documentation across all Pacific MoH and regulatory systems. Tender submissions, registration dossiers, Certificates of Analysis, and stability reports are all submitted in English. For relationship-building and day-to-day communication with local distributors or MoH contacts, having regional partners who can support iTaukei in Fiji and Tok Pisin in PNG adds a layer of trust, but it is not a regulatory requirement.
Conclusion
The South Pacific pharmaceutical market is at an important stage. Healthcare spending is rising. Procurement systems are improving. The Forum of India-Pacific Islands Cooperation is also supporting stronger trade.
Indian API exporters who act now, with the right certifications, proper packaging, and a focus on long-term partnerships, can move ahead of competitors instead of trying to catch up later.
This market does not wait. Zone IVb stability data takes time to prepare. Fiji registration can take almost a year. Donor-funded procurement cycles also follow fixed timelines.
Every delay means someone else moves ahead. Competitors from China, Australia, or even other Indian exporters may already be building the relationships and approvals you will later need to compete with.
Ready to Start?
Start by checking which APIs in your portfolio match Pacific healthcare needs. Review your Zone IVb stability data. Then connect with the Pharmaceuticals Export Promotion Council of India to follow their Pacific trade mission schedule for the year.
